BNT-314
- Generic Name
- BNT-314
Innovent Biologics to Present Breakthrough Clinical Data for IBI363 PD-1/IL-2 Bispecific Antibody at ASCO 2025
• Innovent Biologics will showcase seven oral presentations at ASCO 2025, featuring breakthrough clinical data for its novel PD-1/IL-2α-bias bispecific antibody IBI363 in melanoma, colorectal cancer, and non-small cell lung cancer.
• IBI343, Innovent's anti-CLDN18.2 antibody-drug conjugate, secured an oral presentation slot for its Phase 1b data in pancreatic cancer, demonstrating promising potential in this difficult-to-treat malignancy.
• The company's robust pipeline of bispecific antibodies and ADCs highlights Innovent's growing position as a leader in the "IO+ADC" space, with multiple candidates advancing toward pivotal-stage development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath